Is it possible to treat vascular dementia?

Frontiers of Neurology and Neuroscience

Volumn 24, Issue , 2009, Pages 95-106

  Zekry, Dina ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Hopital de Geriatrie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CANDESARTAN; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; NICERGOLINE; NIMODIPINE; PENTOXIFYLLINE; PLACEBO; RIVASTIGMINE; WARFARIN;

CAROTID ENDARTERECTOMY; CELL DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITION; DIABETES MELLITUS; DISEASE COURSE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INCIDENCE; INTERMITTENT CLAUDICATION; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SMOKING; STROKE;

CLINICAL TRIALS AS TOPIC; DEMENTIA, VASCULAR; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 65349094730     PISSN: 16604431     EISSN: 16622804     Source Type: Book Series    
DOI: 10.1159/000197888     Document Type: Review

References (49)

1. Whitmer RA, Sidney S, Selby J, Claiborne Johnston S, Yaffe K: Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64:277-281.
2. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. J Am Med Assoc 1991;265:3225-3264.
3. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery C T, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A: Randomized double-blind comparison of placebo and active treatment of older patients with isolated systolic hypertension. Lancet 1997;350:757-764.
4. Forette F, Seux ML, Staessen JA Thijs L, Birkenhäger WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;24; 352: 1347-1351.
5. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A, SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886.
6. Trenkwalder P: The Study on COgnition and Prognosis in the Elderly (SCOPE) - recent analyses. J Hypertens Suppl 2006;24:S107 - S114.
7. Zanchetti A, Elmfeldt D: Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) - a review. Blood Press 2006;15:71-79.
8. in t' Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM: Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 2001;22:407-412.
9. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559.
10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
11. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane P W, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER study group: PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
12. Bernick C, Katz R, Smith NL, Rapp S, Bhadelia R, Carlson M, Kuller L, Cardiovascular Health Study Collaborative Research Group: Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology 2005;65:1388-1394.
13. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi P P, Burke GL, Lyketsos CG, Bernick C, Kuller LH: Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005; 62:1047-1051.
14. Li G, Higdon R, Kukull WA, Peskind E, Van Valen Moore K, Tsuang D, van Belle G, McCormick W, Bowen JD, Teri L, Schellenberg GD, Larson EB: Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004;63:1624-1628.
15. Zandi P P, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC, Cache County Study investigators: Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005;62:217-224.
16. Nelson MR, Reid CM, Ames DA, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Krum H, Storey E, Tonkin A, Wolfe R, Woods R, McNeil JJ: Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008;189:105-109.
17. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J, PROGRESS Collaborative Group: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069-1075.
18. Dufouil C, Chalmers J, Coskun O, Besançon V, Bousser MG, Guillon P, MacMahon S, Mazoyer B, Neal B, Woodward M, Tzourio-Mazoyer N, Tzourio C, PROGRESS MRI Substudy Investigators: Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005;112:1644-1650.
19. Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J: Randomized clinical trial of daily aspirin therapy in multi-infarct dementia: a pilot study. J Am Geriatr Soc 1989;37:549-555.
20. Pantoni L, Carosi M, Amigoni S, Mascalchi M, Inzitari D: A preliminary open trial with nimo-dipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacol 1996;19:497-506.
21. Saletu B, Paulus E, Linzmayer L, Anderer P, Semlitsch H V, Grunberger J, Wicke L, Neuhold A, Podreka I: Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-bind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 1995;117:385-395.
22. Black RS, Barclay LL, Nolan KA, Thaler HT, Hardiman S T, Blass JP: Pentoxifylline in cerebrovas-cular dementia. J Am Geriatr Soc 1992;40:237-244.
23. European Pentoxifylline Multi-infarct Dementia Study. Eur Neurol 1996;36:315-321.
24. Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD: Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke. J Cereb Blood Flow Metab 1993;13:526-530.
25. Kittner B, Rossner M, Rother M: Clinical trials in dementia with propentofylline. Ann N Y Acad Sci 1997;826:307-316.
26. Marcusson J, Rother M, Kittner B, Rossner M, Smith RJ, Babic T, Folnegovic-Smalc V, Moller HJ, Labs KH: A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Dement Geriatr Cogn Disord 1997;8:320-328.
27. Birks J, Grimley Evans J: Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2007:CD003120.
28. Grantham C, Geerts H: The rationale behind cholinergic drug treatment for dementia related to cere-brovascular disease. J Neurol Sci 2002;203:131-136.
29. Roman G, Kalaria R: Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 2006;27:1769-1785.
30. Kavirajan H, Schneider LS: Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007;6:782-792.
31. Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R, Donepezil 307 Vascular Dementia Study Group: Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323-2330.
32. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD, Donepezil 308 Study Group: Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003;61: 479-486.
33. Eisai Co Ltd News Release: Eisai reports results from latest donepezil study in vascular dementia http://www.eisai.co.jp/enews/enews200609.html (March 16, 2006).
34. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-1290.
35. Auchus A P, Brashear HR, Salloway S, Korczyn AD, De Deyn P P, Gassmann-Mayer C, GAL-INT-26 Study Group: Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007;69: 448-458.
36. Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, van der Flier WM, Hsu C, Wu S, Lane R: Efficacy, safety and tolerability of rivastig-mine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin 2008;24:2564-2574.
37. Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002;33:1834-1839.
38. Wilcock G, Mobius HJ, Stoffler A: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002;17:297-305.
39. Craig D, Birks J: Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006: CD004746.
40. Craig D, Birks J: Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2005: CD004744.
41. McShane R, Areosa Sastre A, Minakaran N: Memantine for dementia. Cochrane Database Syst Rev 2006:CD003154.
42. Malouf R, Birks J: Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004: CD004395.
43. Roman G, Wilkinson D, Doody R, Black S, Salloway S, Schindler R: Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord 2005;20:338-344.
44. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al: Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-260.
45. McKahn G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
46. American Psychiatry Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatry Association, 1994, pp 143-146.
47. Rosen WG, Terry R, Fuld A, Katzman R, Peck A: Pathological verification verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
48. American Psychiatry Association: Diagnostic and Statistical Manual of Mental Disorders, DSM-III-R. Washington, American Psychiatry Association, 1987.
49. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GHD, McAllister VL, Marshall J, Russel RWR, Symon L: Cerebral blood flow in dementia. Arch Neurol 1975;32:632-637.